PPARγ: The portrait of a target ally to cancer chemopreventive agents

PPAR Research

Volumn , Issue , 2008, Pages

  Sainis, Ioannis ^a   Vareli, Katerina ^a   Karavasilis, Vasilios ^b   Briasoulis, Evangelos ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; APIGENIN; BETA CAROTENE; BETULIC ACID; CAPSAICIN; CAROTENOID; CHRYSIN; CIGLITAZONE; FUCOXANTHIN; GLITAZONE DERIVATIVE; GLYCYRRHIZIC ACID; ISOFLAVONE DERIVATIVE; ISOTRETINOIN; KAEMPFEROL; LINOLEIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RETINOIC ACID; RETINOID X RECEPTOR; ROSIGLITAZONE; TERPENOID DERIVATIVE; TROGLITAZONE;

5' UNTRANSLATED REGION; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER RESEARCH; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; FUNCTIONAL GENOMICS; GLUCOSE HOMEOSTASIS; HUMAN; LOW DRUG DOSE; LUNG CANCER; METASTASIS; MISSENSE MUTATION; NONHUMAN; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; THYROID CANCER; TISSUE DISTRIBUTION;

EID: 53149137806     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/436489     Document Type: Review

References (130)

1. Feige J. N., Gelman L., Michalik L., Desvergne B., Wahli W., From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions Progress in Lipid Research 2006 45 2 120 159
2. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W., Control of the peroxisomal β -oxidation pathway by a novel family of nuclear hormone receptors Cell 1992 68 5 879 887
3. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocrine Reviews 1999 20 5 649 688
4. Chawta A., Repa J. J., Evans R. M., Mangelsdorf D. J., Nuclear receptors and lipid physiology: opening the X-files Science 2001 294 5548 1866 1870
5. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
6. Lock E. A., Mitchell A. M., Elcombe C. R., Biochemical mechanisms of induction of hepatic peroxisome proliferation Annual Review of Pharmacology and Toxicology 1989 29 145 163
7. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease Nature 2000 405 6785 421 424
8. Corton J. C., Anderson S. P., Stauber A., Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators Annual Review of Pharmacology and Toxicology 2000 40 491 518
9. Panigrahy D., Singer S., Shen L. Q., PPAR γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis The Journal of Clinical Investigation 2002 110 7 923 932
10. Nicol C. J., Yoon M., Ward J. M., PPAR γ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis Carcinogenesis 2004 25 9 1747 1755
11. Martinasso G., Oraldi M., Trombetta A., Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines PPAR Research 2007 2007 9
12. Hertz R., Bar-Tana J., Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans Toxicology Letters 1998 102-103 85 90
13. Larsen L. K., Amri E.-Z., Mandrup S., Pacot C., Kristiansen K., Genomic organization of the mouse peroxisome proliferator-activated receptor β / δ gene: alternative promoter usage and splicing yield transcripts exhibiting differential translational efficiency Biochemical Journal 2002 366 3 767 775
14. Berger J., Moller D. E., The mechanisms of action of PPARs Annual Review of Medicine 2002 53 409 435
15. Lehrke M., Lazar M. A., The many faces of PPAR γ Cell 2005 123 6 993 999
16. Beamer B. A., Negri C., Yen C.-J., Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR γ) gene Biochemical and Biophysical Research Communications 1997 233 3 756 759
17. Fajas L., Auboeuf D., Raspé E., The organization, promoter analysis, and expression of the human PPAR γ gene The Journal of Biological Chemistry 1997 272 30 18779 18789
18. Fajas L., Fruchart J.-C., Auwerx J., PPAR γ 3 mRNA: a distinct PPAR γ mRNA subtype transcribed from an independent promoter FEBS Letters 1998 438 1-2 55 60
19. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer Genes & Development 1994 8 10 1224 1234
20. Mukherjee R., Jow L., Croston G. E., Paterniti J. R. Jr., Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR γ 2 versus PPAR γ 1 and activation with retinoid X receptor agonists and antagonists The Journal of Biological Chemistry 1997 272 12 8071 8076
21. Nolte R. T., Wisely G. B., Westin S., Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor- γ Nature 1998 395 6698 137 143
22. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., Berkenstam A., Crystal structure of the ligand binding domain of the human nuclear receptor PPAR γ The Journal of Biological Chemistry 1998 273 47 31108 31112
23. Issemann I., Prince R. A., Tugwood J. D., Green S., The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs The Journal of Molecular Endocrinology 1993 11 1 37 47
24. Kliewer S. A., Umesono K., Noonan D. J., Heyman R. A., Evans R. M., Convergence of 9- cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors Nature 1992 358 6389 771 774
25. Burgermeister E., Seger R., MAPK kinases as nucleo-cytoplasmic shuttles for PPAR γ Cell Cycle 2007 6 13 1539 1548
26. Hu E., Kim J. B., Sarraf P., Spiegelman B. M., Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR γ Science 1996 274 5295 2100 2103
27. Adams M., Reginato M. J., Shao D., Lazar M. A., Chatterjee V. K., Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site The Journal of Biological Chemistry 1997 272 8 5128 5132
28. Burns K. A., Vanden Heuvel J. P., Modulation of PPAR activity via phosphorylation Biochimica et Biophysica Acta 2007 1771 8 952 960
29. Shao D., Rangwala S. M., Bailey S. T., Krakow S. L., Reginato M. J., Lazar M. A., Interdomain communication regulating ligand binding by PPAR- γ Nature 1998 396 6709 377 380
30. Ristow M., Müller-Wieland D., Pfeiffer A., Krone W., Kahn C. R., Obesity associated with a mutation in a genetic regulator of adipocyte differentiation The New England Journal of Medicine 1998 339 14 953 959
31. Lazennec G., Canaple L., Saugy D., Wahli W., Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators Molecular Endocrinology 2000 14 12 1962 1975
32. Floyd Z. E., Stephens J. M., Interferon- γ -mediated activation and ubiquitin-proteasome-dependent degradation of PPAR γ in adipocytes The Journal of Biological Chemistry 2002 277 6 4062 4068
33. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., Seger R., Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ Molecular and Cellular Biology 2007 27 3 803 817
34. Michalik L., Desvergne B., Wahli W., Peroxisome-proliferator-activated receptors and cancers: complex stories Nature Reviews Cancer 2004 4 1 61 70
35. Grommes C., Landreth G. E., Sastre M., Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment Molecular Pharmacology 2006 70 5 1524 1533
36. Cui Y., Lu Z., Bai L., Shi Z., Zhao W.-E., Zhao B., β -carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor γ expression and reactive oxygen species production in MCF-7 cancer cells European Journal of Cancer 2007 43 17 2590 2601
37. Sun H., Berquin I. M., Owens R. T., O'Flaherty J. T., Edwards I. J., Peroxisome proliferator-activated receptor β -mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells Cancer Research 2008 68 8 2912 2919
38. Borbath I., Leclercq I., Moulin P., Sempoux C., Horsmans Y., The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver European Journal of Cancer 2007 43 11 1755 1763
39. Folkman J., Angiogenesis: an organizing principle for drug discovery? Nature Reviews Drug Discovery 2007 6 4 273 286
40. Giaginis C., Tsantili-Kakoulidou A., Theocharis S., Peroxisome proliferator-activated receptor- γ ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer PPAR Research 2008 2008 12
41. Panigrahy D., Huang S., Kieran M. W., Kaipainen A., PPAR γ as a therapeutic target for tumor angiogenesis and metastasis Cancer Biology and Therapy 2005 4 7 687 693
42. Keshamouni V. G., Arenberg D. A., Reddy R. C., Newstead M. J., Anthwal S., Standiford T. J., PPAR- γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer Neoplasia 2005 7 3 294 301
43. Huang H., Campbell S. C., Bedford D. F., Peroxisome proliferator- activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510 Molecular Cancer Research 2004 2 10 541 550
44. McCarty M. F., Barroso-Aranda J., Contreras F., PPARgamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation Medical Hypotheses 2008 70 2 419 423
45. Katoh M., Katoh M., WNT signaling pathway and stem cell signaling network Clinical Cancer Research 2007 13 14 4042 4045
46. Galli A., Mello T., Ceni E., Surrenti E., Surrenti C., The potential of antidiabetic thiazolidinediones for anticancer therapy Expert Opinion on Investigational Drugs 2006 15 9 1039 1049
47. Yee L. D., Williams N., Wen P., Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers Clinical Cancer Research 2007 13 1 246 252
48. Lefebvre A.-M., Paulweber B., Fajas L., Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells Journal of Endocrinology 1999 162 3 331 340
49. Sarraf P., Mueller E., Jones D., Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Medicine 1998 4 9 1046 1052
50. Gupta R. A., Sarraf P., Brockman J. A., Peroxisome proliferator-activated receptor γ and transforming growth factor- β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22 The Journal of Biological Chemistry 2003 278 9 7431 7438
51. Chang A. J., Song D. H., Wolfe M. M., Attenuation of peroxisome proliferator-activated receptor γ (PPAR γ) mediates gastrin-stimulated colorectal cancer cell proliferation The Journal of Biological Chemistry 2006 281 21 14700 14710
52. Yamazaki K., Shimizu M., Okuno M., Synergistic effects of RXR α and PPAR γ ligands to inhibit growth in human colon cancer cells-phosphorylated RXR α is a critical target for colon cancer management Gut 2007 56 11 1557 1563
53. Girnun G. D., Smith W. M., Drori S., APC-dependent suppression of colon carcinogenesis by PPAR γ Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13771 13776
54. Saez E., Tontonoz P., Nelson M. C., Activators of the nuclear receptor PPAR γ enhance colon polyp formation Nature Medicine 1998 4 9 1058 1061
55. Niho N., Takahashi M., Shoji Y., Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR γ ligand Cancer Science 2003 94 11 960 964
56. McAlpine C. A., Barak Y., Matise I., Cormier R. T., Intestinal-specific PPAR γ deficiency enhances tumorigenesis in Apc Min/+ mice International Journal of Cancer 2006 119 10 2339 2346
57. Thompson E. A., PPAR γ physiology and pathology in gastrointestinal epithelial cells Molecules and Cells 2007 24 2 167 176
58. Kulke M. H., Demetri G. D., Sharpless N. E., A phase II study of troglitazone, an activator of the PPAR γ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer Cancer Journal 2002 8 5 395 399
59. Bach P. B., Silvestri G. A., Hanger M., Jett J. R., Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 2007 132 3, supplement 69S 77S
60. Soria J.-C., Kim E. S., Fayette J., Lantuejoul S., Deutsch E., Hong W. K., Chemoprevention of lung cancer The Lancet Oncology 2003 4 11 659 669
61. Hirsch F. R., Lippman S. M., Advances in the biology of lung cancer chemoprevention Journal of Clinical Oncology 2005 23 14 3186 3197
62. Chang T.-H., Szabo E., Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer Cancer Research 2000 60 4 1129 1138
63. Tsubouchi Y., Sano H., Kawahito Y., Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor- γ agonists through induction of apoptosis Biochemical and Biophysical Research Communications 2000 270 2 400 405
64. Wick M., Hurteau G., Dessev C., Peroxisome proliferator-activated receptor- γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth Molecular Pharmacology 2002 62 5 1207 1214
65. Lee S. Y., Hur G. Y., Jung K. H., PPAR- γ agonist increase gefitinib's antitumor activity through PTEN expression Lung Cancer 2006 51 3 297 301
66. Han S., Sidell N., Fisher P. B., Roman J., Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells Clinical Cancer Research 2004 10 6 1911 1919
67. Keshamouni V. G., Reddy R. C., Arenberg D. A., Peroxisome proliferator-activated receptor- γ activation inhibits tumor progression in non-small-cell lung cancer Oncogene 2004 23 1 100 108
68. Han S., Rivera H. N., Roman J., Peroxisome proliferator-activated receptor- γ ligands inhibit α 5 integrin gene transcription in non-small cell lung carcinoma cells American Journal of Respiratory Cell and Molecular Biology 2005 32 4 350 359
69. Govindarajan R., Ratnasinghe L., Simmons D. L., Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes Journal of Clinical Oncology 2007 25 12 1476 1481
70. Nissen S. E., Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes The New England Journal of Medicine 2007 356 24 2457 2471
71. Nemenoff R. A., Peroxisome proliferator-activated receptor- γ in lung cancer: defining specific versus "off-target" effectors Journal of Thoracic Oncology 2007 2 11 989 992
72. Hazra S., Batra R. K., Tai H. H., Sharma S., Cui X., Dubinett S. M., Pioglitazone and rosiglitazone decrease prostaglandin E 2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase Molecular Pharmacology 2007 71 6 1715 1720
73. Zou W., Liu X., Yue P., Khuri F. R., Sun S.-Y., PPAR γ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells Cancer Biology and Therapy 2007 6 1 99 106
74. Yao C.-J., Lai G.-M., Chan C.-F., Cheng A.-L., Yang Y.-Y., Chuang S.-E., Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone International Journal of Cancer 2006 118 3 773 779
75. Avis I., Martínez A., Tauler J., Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition Cancer Research 2005 65 10 4181 4190
76. Dorgan J. F., Sowell A., Swanson C. A., Relationships of serum carotenoids, retinol, α -tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States) Cancer Causes & Control 1998 9 1 89 97
77. Toniolo P., Van Kappel A. L., Akhmedkhanov A., Serum carotenoids and breast cancer American Journal of Epidemiology 2001 153 12 1142 1147
78. Mueller E., Sarraf P., Tontonoz P., Terminal differentiation of human breast cancer through PPAR γ Molecular Cell 1998 1 3 465 470
79. Mehta R. G., Williamson E., Patel M. K., Koeffler H. P., A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions Journal of the National Cancer Institute 2000 92 5 418 423
80. Elstner E., Müller C., Koshizuka K., Ligands for peroxisome proliferator-activated receptory and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8806 8811
81. Burstein H. J., Demetri G. D., Mueller E., Sarraf P., Spiegelman B. M., Winer E. P., Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study Breast Cancer Research and Treatment 2003 79 3 391 397
82. Mueller E., Smith M., Sarraf P., Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10990 10995
83. Sabichi A. L., Subbarayan V., Llansa N., Lippman S. M., Menter D. G., Peroxisome proliferator-activated receptor- γ suppresses cyclooxygenase-2 expression in human prostate cells Cancer Epidemiology Biomarkers & Prevention 2004 13 11, part 1 1704 1709
84. Shiau C.-W., Yang C.-C., Kulp S. K., Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR γ Cancer Research 2005 65 4 1561 1569
85. Hisatake J.-I., Ikezoe T., Carey M., Holden S., Tomoyasu S., Koeffler H. P., Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer Cancer Research 2000 60 19 5494 5498
86. Wu W., Celestino J., Milam M. R., Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model International Journal of Gynecological Cancer 2008 18 2 329 338
87. Elnemr A., Ohta T., Iwata K., PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells International Journal of Oncology 2000 17 6 1157 1164
88. Motomura W., Okumura T., Takahashi N., Obara T., Kohgo Y., Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p 27 Kip 1 in human pancreatic carcinoma cells Cancer Research 2000 60 19 5558 5564
89. Toyota M., Miyazaki Y., Kitamura S., Peroxisome proliferator-activated receptor γ reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1 Life Sciences 2002 70 13 1565 1575
90. Tontonoz P., Singer S., Forman B. M., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor Proceedings of the National Academy of Sciences of the United States of America 1997 94 1 237 241
91. Debrock G., Vanhentenrijk V., Sciot R., Debiec-Rychter M., Oyen R., Van Oosterom A., A phase II trial with rosiglitazone in liposarcoma patients British Journal of Cancer 2003 89 8 1409 1412
92. Kroll T. G., Sarraf P., Pecciarini L., PAX8-PPAR γ 1 fusion in oncogene human thyroid carcinoma Science 2000 289 5483 1357 1360
93. Shen W. T., Chung W.-Y., Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor- γ agonists Thyroid 2005 15 6 594 599
94. Klopper J. P., Hays W. R., Sharma V., Baumbusch M. A., Hershman J. M., Haugen B. R., Retinoid X receptor- γ and peroxisome proliferator-activated receptor- γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment Molecular Cancer Therapeutics 2004 3 8 1011 1120
95. Fabiani R., De Bartolomeo A., Rosignoli P., Servili M., Montedoro G. F., Morozzi G., Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis European Journal of Cancer Prevention 2002 11 4 351 358
96. D'Incalci M., Steward W. P., Gescher A. J., Use of cancer chemopreventive phytochemicals as antineoplastic agents The Lancet Oncology 2005 6 11 899 904
97. Lagiou P., Rossi M., Lagiou A., Tzonou A., La Vecchia C., Trichopoulos D., Flavonoid intake and liver cancer: a case-control study in Greece Cancer Causes & Control 2008 1 6
98. Linseisen J., Rohrmann S., Miller A. B., Fruit and vegetable consumption and lung cancer risk: updated information from the European Prospective Investigation into Cancer and Nutrition (EPIC) International Journal of Cancer 2007 121 5 1103 1114
99. Ko J. K. S., Leung W. C., Ho W. K., Chiu P., Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene European Journal of Pharmacology 2007 559 1 1 13
100. Shishodia S., Sethi G., Konopleva M., Andreeff M., Aggarwal B. B., A synthetic triterpenoid, CDDO-Me, inhibits I κ B α kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor κ B-regulated gene products in human leukemic cells Clinical Cancer Research 2006 12 6 1828 1838
101. Amico V., Barresi V., Condorelli D., Spatafora C., Tringali C., Antiproliferative terpenoids from almond hulls (Prunus dulcis): identification and structure-activity relationships Journal of Agricultural and Food Chemistry 2006 54 3 810 814
102. Hsieh C.-L., Tseng M.-H., Shao Y.-Y., C35 terpenoids from the bark of Calocedrus macrolepis var. formosana with activity against human cancer cell lines Journal of Natural Products 2006 69 11 1611 1613
103. Lapillonne H., Konopleva M., Tsao T., Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells Cancer Research 2003 63 18 5926 5939
104. Chintharlapalli S., Papineni S., Jutooru I., McAlees A., Safe S., Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ agonists in colon cancer cells Molecular Cancer Therapeutics 2007 6 5 1588 1598
105. Chintharlapalli S., Papineni S., Liu S., 2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor γ in colon and pancreatic cancer cells Carcinogenesis 2007 28 11 2337 2346
106. Ho C.-C., Huang P.-H., Huang H.-Y., Chen Y.-H., Yang P.-C., Hsu S.-M., Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation American Journal of Pathology 2002 161 5 1647 1656
107. Burgermeister E., Tencer L., Liscovitch M., Peroxisome proliferator-activated receptor- γ upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells Oncogene 2003 22 25 3888 3900
108. Ricketts M.-L., Moore D. D., Banz W. J., Mezei O., Shay N. F., Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review The Journal of Nutritional Biochemistry 2005 16 6 321 330
109. Dang Z.-C., Audinot V., Papapoulos S. E., Boutin J. A., Löwik C. W. G. M., Peroxisome proliferator-activated receptor γ (PPAR γ) as a molecular target for the soy phytoestrogen genistein The Journal of Biological Chemistry 2003 278 2 962 967
110. Liang Y.-C., Tsai S.-H., Tsai D.-C., Lin-Shiau S.-Y., Lin J.-K., Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor- γ by flavonoids in mouse macrophages FEBS Letters 2001 496 1 12 18
111. Fischer L., Mahoney C., Jeffcoat A. R., Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia Nutrition and Cancer 2004 48 2 160 170
112. Kumar N. B., Krischer J. P., Allen K., Safety of purified isoflavones in men with clinically localized prostate cancer Nutrition and Cancer 2007 59 2 169 175
113. Kumar N. B., Krischer J. P., Allen K., A phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer Nutrition and Cancer 2007 59 2 163 168
114. Takimoto C. H., Glover K., Huang X., Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer Cancer Epidemiology Biomarkers & Prevention 2003 12 11, part 1 1213 1221
115. Hosokawa M., Kudo M., Maeda H., Kohno H., Tanaka T., Miyashita K., Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPAR γ ligand, troglitazone, on colon cancer cells Biochimica et Biophysica Acta 2004 1675 1-3 113 119
116. Maggiora M., Bologna M., Cerù M. P., An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines International Journal of Cancer 2004 112 6 909 919
117. Bocca C., Bozzo F., Francica S., Colombatto S., Miglietta A., Involvement of PPAR γ and E-cadherin/ β -catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF-7 cells International Journal of Cancer 2007 121 2 248 256
118. Tsuzuki T., Kawakami Y., Tumor angiogenesis suppression by α -eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor γ Carcinogenesis 2008 29 4 797 806
119. Yasui Y., Suzuki R., Kohno H., 9trans,11trans conjugated linoleic acid inhibits the development of azoxymethane-induced colonic aberrant crypt foci in rats Nutrition and Cancer 2007 59 1 82 91
120. Sasaki T., Yoshida K., Shimura H., Inhibitory effect of linoleic acid on transformation of IEC6 intestinal cells by in vitro azoxymethane treatment International Journal of Cancer 2006 118 3 593 599
121. Bull A. W., Steffensen K. R., Leers J., Rafter J. J., Activation of PPAR γ in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR γ Carcinogenesis 2003 24 11 1717 1722
122. Zuo X., Wu Y., Morris J. S., Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity Oncogene 2006 25 8 1225 1241
123. Kim C.-S., Park W.-H., Park J.-Y., Capsaicin, a spicy component of hot pepper, induces apoptosis by activation of the peroxisome proliferator-activated receptor γ in HT-29 human colon cancer cells Journal of Medicinal Food 2004 7 3 267 273
124. Mori A., Lehmann S., O'Kelly J., Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells Cancer Research 2006 66 6 3222 3229
125. Jun H.-S., Park T., Lee C. K., Capsaicin induced apoptosis of B16-F10 melanoma cells through down-regulation of Bcl-2 Food and Chemical Toxicology 2007 45 5 708 715
126. Surh Y.-J., Lee S. S., Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Food and Chemical Toxicology 1996 34 3 313 316
127. Yoshitani S. I., Tanaka T., Kohno H., Takashima S., Chemoprevention of azoxymethane-induced rat colon carcinogenesis by dietary capsaicin and rotenone International Journal of Oncology 2001 19 5 929 939
128. Clapper M. L., Szarka C. E., Pfeiffer G. R., Preclinical and clinical evaluation of broccoli supplements as inducers of glutathione S -transferase activity Clinical Cancer Research 1997 3 1 25 30
129. Sharma R. A., Ireson C. R., Verschoyle R. D., Effects of dietary curcumin on glutathione S -transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels Clinical Cancer Research 2001 7 5 1452 1458
130. Park E. Y., Cho I. J., Kim S. G., Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S -transferase gene by the peroxisome proliferator-activated receptor- γ and retinoid X receptor heterodimer Cancer Research 2004 64 10 3701 3713